Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1350594 | 1.00 | AKT1 (0.50) | AKT1PDE10APIM1HSD11B1PRKCQ | |
| SCHEMBL18239395 | 1.00 | AKT1 (0.50) | AKT1PDE10APIM1HSD11B1PRKCQ | |
| Hydrochloric Acid SCHEMBL18228382 | 0.98 | AKT1 (0.49) | AKT1PDE10APIM1HSD11B1PRKCQ | |
| SCHEMBL2804196 | 0.90 | HSD11B1 (0.49) | PIM1HSD11B1MALT1KMT2AHRH3 | |
| SCHEMBL11962830 | 0.86 | HSD11B1 (0.45) | PDE10AHSD11B1MALT1KMT2A | |
| SCHEMBL10094610 | 0.86 | HSD11B1 (0.45) | PDE10AHSD11B1MALT1KMT2A | |
| SCHEMBL25888999 | 0.86 | HSD11B1 (0.45) | PDE10AHSD11B1MALT1KMT2A | |
| SCHEMBL17206944 | 0.82 | HSD11B1 (0.50) | PDE10AHSD11B1MALT1KMT2A | |
| SCHEMBL1350750 | 0.81 | MALT1 (0.50) | AKT1PDE10AHSD11B1PRKCQHRH4 | |
| SCHEMBL1350753 | 0.81 | MALT1 (0.50) | AKT1PDE10AHSD11B1PRKCQHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063078-B2 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | GLAXOSMITHKLINE LLC (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2298757-A2 | Urea compounds active as vanilloid receptor antagonist for the treatment of pain | Glaxo Group Limited (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | SMITHKLINE BEECHAM PLC. (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-1425277-B8 | UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | GLAXO GROUP LTD (GB) | 2009-04-01 | — | — | EP | disclosed |
| EP-2036902-A2 | Urea compounds active as vanilloid receptor antagonist for the treatment of pain | Glaxo Group Limited (GB) | 2009-03-18 | — | — | EP | disclosed |
| EP-1425277-A2 | UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | SmithKline Beecham P.L.C. (GB) | 2004-06-09 | — | — | EP | disclosed |
| WO-2004024710-A1 | UREA COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
| WO-2003022809-A2 | UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | TRPV1, OPRL1, UTS2R | AKT1 4433/4885PDE10A 371/4885PIM1 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.